A federal jury is preparing to hear a bellwether case regarding the alleged cancer-causing diabetes drug Actos, manufactured by Asia’s largest drugmaker, Takeda Pharmaceuticals.
The plaintiff in Terrence Allen et ux. v. Takeda Pharmaceuticals North America Inc. et al alleges damages in excess of $75,000 after he says he developed bladder cancer because of his use of the drug for treatment of Type II diabetes. The drug was approved by the FDA for U.S. sales in 1999, but the plaintiff alleges the drugmaker knew then that the drug, with a brand name of Pioglitazone, caused bladder cancer. This risks, it is alleged, were downplayed to federal regulators and actively concealed from doctors and patients.
The trial, one of the first of some 3,000 cases pending across the country, is taking place in the U.S. District Court, Western District of Louisiana (Lafayette). Other plaintiffs are watching closely, as the outcome here could affect those in thousands of other cases. As our Boston Actos bladder cancer attorneys understand it, the trial, expected to span about six weeks, has gotten off to a rough start for the defense.
Continue reading